| Zeit | Aktuelle Nachrichten
| | Leser | Medien |
|---|
| 23.05.
| Arqule Down 15.9% Since SmarTrend Downtrend Call | | 1 | SmarTrend |
| 21.05.
| ArQule und Daiichi Sankyo geben den abschluss der patientenrekrutierung in phase 3 der klinischen studie von tivantinib gegen nicht-kleinzelligen lungenkrebs bekannt | | 60 | news aktuell |
| Woburn, Massachusetts Und Tokio (ots/PRNewswire) - ArQule, Inc. und Daiichi Sankyo, Co., Ltd (TSE 4568) gaben heute bekannt, dass die Patientenrekrutierung für die zentrale randomisierte, doppelblinde...
Mehr lesen zu:
ArQule und Daiichi Sankyo geben den abschluss der patientenrekrutierung in phase 3 der klinischen studie von tivantinib gegen nicht-kleinzelligen lungenkrebs bekannt | |
| 21.05.
| Arqule Earnings Review: 18 Days after Announcement Shares Down 13.7% | | 1 | SmarTrend |
| 21.05.
| ArQule, Daiichi complete patient recruitment in Phase III NSCLC trial | | 2 | Pharma Bus Review |
| 18.05.
| Arqule and Daiichi Sankyo Announce Completion of Patient Recruitment in Phase 3 Clinical Trial of Tivantinib in Non-small Cell Lung Cancer | | 62 | PR Newswire |
| WOBURN, Massachusetts and TOKYO, May 18, 2012 /PRNewswire/ --
ArQule, Inc. (Nasdaq: ARQL) and Daiichi Sankyo, Co., Ltd. (TSE 4568) today announced that recruitment of patients has been completed...
Mehr lesen zu:
Arqule and Daiichi Sankyo Announce Completion of Patient Recruitment in Phase 3 Clinical Trial of Tivantinib in Non-small Cell Lung Cancer | |
| 18.05.
| ArQule and Daiichi Sankyo Announce Completion of Patient Recruitment in Phase 3 Clinical Trial of Tivantinib in Non-Small Cell Lung Cancer | | 43 | Business Wire |
| ArQule, Inc. (Nasdaq: ARQL) and Daiichi Sankyo, Co., Ltd. (TSE 4568)
today announced that recruitment of patients has been completed in the
randomized, double-blind, controlled...
Mehr lesen zu:
ArQule and Daiichi Sankyo Announce Completion of Patient Recruitment in Phase 3 Clinical Trial of Tivantinib in Non-Small Cell Lung Cancer | |
| 17.05.
| Ariad Pharmaceuticals, ArQule, Exelixis, Aveo, Other Cancer Drug Stocks Fall | | 11 | Minyanville |
| 17.05.
| ArQule (ARQL), Daiichi Sankyo Say Bivantinib Phase 2 Met Primary Endpoint; to Present Data at ASCO | | 3 | StreetInsider.com |
| 03.05.
| ARQULE INC - 10-Q, Quarterly Report | | 5 | SEC Filings |
| 03.05.
| ArQule Reports First Quarter 2012 Financial Results | | 23 | Business Wire |
| Conference call scheduled today at 9:00 a.m. eastern time
ArQule, Inc. (NASDAQ: ARQL) today announced its financial results for
the first quarter of...
Mehr lesen zu:
ArQule Reports First Quarter 2012 Financial Results | |
| 02.05.
| Arqule Shares Up 17.1% Since SmarTrend's Buy Recommendation | | - | SmarTrend |
| 26.04.
| ArQule to Report First Quarter 2012 Financial Results on May 3, 2012 | | 29 | Business Wire |
| ArQule, Inc. (NASDAQ: ARQL) today announced that it will report its
financial results for the first quarter of 2012 on Thursday, May 3, 2012
at 7:00 a.m. eastern time....
Mehr lesen zu:
ArQule to Report First Quarter 2012 Financial Results on May 3, 2012 | |
| 18.04.
| Arqule Shares Up 20.5% Since SmarTrend's Buy Recommendation | | 2 | SmarTrend |
| 16.04.
| ArQule Closes Offering Of 8 Mln Shares At $7.30/shr | | 46 | AFX News |
| WASHINGTON (dpa-AFX) - Healthcare company ArQule, Inc. (ARQL) said Monday it
has completed the public offering of 8,222,500 shares of its common stock,
including 1,072,500 shares issued...
Mehr lesen zu:
ArQule Closes Offering Of 8 Mln Shares At $7.30/shr | |
| 16.04.
| ArQule (ARQL) Completes 8.2M Offering at $7.30/Share | | - | StreetInsider.com |
| 16.04.
| ArQule Announces Completion of Common Stock Offering with Full Exercise of Option to Purchase Additional Shares | | 38 | Business Wire |
| ArQule, Inc. (NASDAQ: ARQL) today announced the completion of its
previously announced public offering of 8,222,500 shares of its common
stock, including 1,072,500 shares...
Mehr lesen zu:
ArQule Announces Completion of Common Stock Offering with Full Exercise of Option to Purchase Additional Shares | |
| 11.04.
| Arqule Trading Higher Today on Above-Average Volume, Consistent With Trend | | - | SmarTrend |
| 11.04.
| 29.7% Return Seen to Date on SmarTrend Arqule Call | | 2 | SmarTrend |
| 11.04.
| ArQule Announces Pricing For Public Offering Of 7.15 Mln Shares | | 29 | AFX News |
| WASHINGTON (dpa-AFX) - ArQule Inc (ARQL) Wednesday announced that it has
priced an underwritten public offering of 7.15 million shares of common stock at
a price of $7.30 per share.The company...
Mehr lesen zu:
ArQule Announces Pricing For Public Offering Of 7.15 Mln Shares | |
| 11.04.
| ArQule Prices Public Offering of Common Stock | | 39 | Business Wire |
| ArQule, Inc. (NASDAQ: ARQL) today announced the pricing of an
underwritten public offering of 7,150,000 shares of its common stock at
a price of $7.30 per share. The net...
Mehr lesen zu:
ArQule Prices Public Offering of Common Stock | |
